A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

The objective of this study is to determine any problems or questions associated with Zavicefta after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination Guideline of New Drugs".

• Serious adverse event/adverse drug reaction
• Unexpected adverse event/adverse drug reaction that have not been reflected in the approved drug label.
• Known adverse drug reaction
• Non-serious adverse drug reaction
• Other safety and effectiveness information As required for any new medication approved by Ministry of Food and Drug Safety (MFDS), information on safety and effectiveness of new medication should be researched on certain number of subjects taking the drug in the setting of routine practice during the initial 6 years after the approval of new drug. This reserach shall begin after approval of marketing in Korea by MFDS.

• Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:

• Complicated intra-abdominal infection (cIAI)
• Complicated urinary tract infection (cUTI), including pyelonephritis
• Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
• Other aerobic Gram-negative organism infection with limited treatment options
• Adults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:

•Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.

• Patients are treated with Zavicefta for the first time
• Patients have signed the data privacy statement.